Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Harvard Bioscience, Inc. (HBIO) had Normalized Pre-Tax Income of $-2.25M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$20.45M |
|
$-2.28M |
|
$8.92M |
|
$11.53M |
|
$21.27M |
|
$-0.82M |
|
$-1.44M |
|
$-2.25M |
|
|
Normalized Pre-Tax Income |
$-2.25M |
$-2.28M |
|
$-2.28M |
|
$-2.28M |
|
$-2.28M |
|
$-0.82M |
|
$1.01M |
|
44.30M |
|
44.30M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$44.97M |
|
$4.91M |
|
$35.12M |
|
$80.09M |
|
$55.20M |
|
-- |
|
$9.16M |
|
$64.36M |
|
$15.73M |
|
$-3.56M |
|
$15.73M |
|
44.53M |
|
| Cash Flow Statement Financials | |
$5.74M |
|
$-0.92M |
|
$-2.46M |
|
$4.11M |
|
$7.44M |
|
$3.33M |
|
$1.07M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.81 |
|
-- |
|
-- |
|
-- |
|
2.22 |
|
56.40% |
|
-4.00% |
|
-4.00% |
|
-- |
|
-11.02% |
|
-11.16% |
|
$5.14M |
|
-- |
|
-- |
|
-- |
|
0.26 |
|
0.40 |
|
1.71 |
|
52.53 |
|
-14.50% |
|
64.14% |
|
-2.85% |
|
-14.50% |
|
$0.35 |
|
$0.12 |
|
$0.13 |
|